nodes	percent_of_prediction	percent_of_DWPC	metapath
Zafirlukast—ABCG2—Fluorouracil—urinary bladder cancer	0.0655	0.103	CbGbCtD
Zafirlukast—ABCG2—Carboplatin—urinary bladder cancer	0.0651	0.102	CbGbCtD
Zafirlukast—ABCG2—Cisplatin—urinary bladder cancer	0.0556	0.0872	CbGbCtD
Zafirlukast—ABCG2—Etoposide—urinary bladder cancer	0.0546	0.0856	CbGbCtD
Zafirlukast—PTGS1—Etoposide—urinary bladder cancer	0.0504	0.079	CbGbCtD
Zafirlukast—CYP3A4—Thiotepa—urinary bladder cancer	0.0435	0.0682	CbGbCtD
Zafirlukast—CYP2E1—Etoposide—urinary bladder cancer	0.039	0.0611	CbGbCtD
Zafirlukast—ABCG2—Doxorubicin—urinary bladder cancer	0.0373	0.0584	CbGbCtD
Zafirlukast—ABCG2—Methotrexate—urinary bladder cancer	0.0361	0.0566	CbGbCtD
Zafirlukast—CYP2C8—Fluorouracil—urinary bladder cancer	0.0349	0.0547	CbGbCtD
Zafirlukast—CYP2C8—Etoposide—urinary bladder cancer	0.0291	0.0456	CbGbCtD
Zafirlukast—CYP1A2—Fluorouracil—urinary bladder cancer	0.027	0.0423	CbGbCtD
Zafirlukast—CYP2C9—Fluorouracil—urinary bladder cancer	0.0243	0.0381	CbGbCtD
Zafirlukast—CYP1A2—Etoposide—urinary bladder cancer	0.0225	0.0353	CbGbCtD
Zafirlukast—CYP2C9—Cisplatin—urinary bladder cancer	0.0207	0.0324	CbGbCtD
Zafirlukast—CYP2D6—Doxorubicin—urinary bladder cancer	0.0127	0.0198	CbGbCtD
Zafirlukast—CYP3A4—Etoposide—urinary bladder cancer	0.0118	0.0185	CbGbCtD
Zafirlukast—CYSLTR2—female reproductive system—urinary bladder cancer	0.00857	0.107	CbGeAlD
Zafirlukast—CYP3A4—Doxorubicin—urinary bladder cancer	0.00805	0.0126	CbGbCtD
Zafirlukast—CYSLTR1—prostate gland—urinary bladder cancer	0.00591	0.0738	CbGeAlD
Zafirlukast—CYP2C19—urine—urinary bladder cancer	0.00566	0.0706	CbGeAlD
Zafirlukast—CYP1A2—urine—urinary bladder cancer	0.00462	0.0577	CbGeAlD
Zafirlukast—CYP2C9—urine—urinary bladder cancer	0.00439	0.0547	CbGeAlD
Zafirlukast—CYSLTR1—smooth muscle tissue—urinary bladder cancer	0.00419	0.0523	CbGeAlD
Zafirlukast—CYP2E1—urine—urinary bladder cancer	0.00416	0.0519	CbGeAlD
Zafirlukast—CYP3A4—urine—urinary bladder cancer	0.00334	0.0417	CbGeAlD
Zafirlukast—CYP2D6—urine—urinary bladder cancer	0.00329	0.0411	CbGeAlD
Zafirlukast—CYSLTR1—female reproductive system—urinary bladder cancer	0.00323	0.0403	CbGeAlD
Zafirlukast—CYSLTR1—vagina—urinary bladder cancer	0.00292	0.0364	CbGeAlD
Zafirlukast—CYSLTR1—lymph node—urinary bladder cancer	0.00189	0.0236	CbGeAlD
Zafirlukast—ABCG2—prostate gland—urinary bladder cancer	0.00172	0.0215	CbGeAlD
Zafirlukast—CYP2E1—prostate gland—urinary bladder cancer	0.00149	0.0186	CbGeAlD
Zafirlukast—ABCG2—seminal vesicle—urinary bladder cancer	0.00146	0.0182	CbGeAlD
Zafirlukast—PTGS1—prostate gland—urinary bladder cancer	0.00144	0.0179	CbGeAlD
Zafirlukast—CYP2E1—seminal vesicle—urinary bladder cancer	0.00126	0.0158	CbGeAlD
Zafirlukast—PTGS1—seminal vesicle—urinary bladder cancer	0.00122	0.0152	CbGeAlD
Zafirlukast—CYP2C8—renal system—urinary bladder cancer	0.00121	0.0151	CbGeAlD
Zafirlukast—ABCG2—urethra—urinary bladder cancer	0.00115	0.0144	CbGeAlD
Zafirlukast—CYP1A2—renal system—urinary bladder cancer	0.00113	0.0141	CbGeAlD
Zafirlukast—PTGS1—epithelium—urinary bladder cancer	0.00106	0.0132	CbGeAlD
Zafirlukast—PTGS1—smooth muscle tissue—urinary bladder cancer	0.00102	0.0127	CbGeAlD
Zafirlukast—CYP2E1—renal system—urinary bladder cancer	0.00102	0.0127	CbGeAlD
Zafirlukast—CYP2C19—vagina—urinary bladder cancer	0.001	0.0125	CbGeAlD
Zafirlukast—CYP2E1—urethra—urinary bladder cancer	0.000999	0.0125	CbGeAlD
Zafirlukast—PTGS1—renal system—urinary bladder cancer	0.00098	0.0122	CbGeAlD
Zafirlukast—CYP2C8—female reproductive system—urinary bladder cancer	0.000967	0.0121	CbGeAlD
Zafirlukast—CYP2C8—vagina—urinary bladder cancer	0.000875	0.0109	CbGeAlD
Zafirlukast—CYP2C9—female reproductive system—urinary bladder cancer	0.000859	0.0107	CbGeAlD
Zafirlukast—ABCG2—vagina—urinary bladder cancer	0.000851	0.0106	CbGeAlD
Zafirlukast—CYP3A4—renal system—urinary bladder cancer	0.000818	0.0102	CbGeAlD
Zafirlukast—CYP2E1—female reproductive system—urinary bladder cancer	0.000814	0.0102	CbGeAlD
Zafirlukast—CYP2D6—renal system—urinary bladder cancer	0.000805	0.0101	CbGeAlD
Zafirlukast—PTGS1—female reproductive system—urinary bladder cancer	0.000784	0.00979	CbGeAlD
Zafirlukast—PTGS1—vagina—urinary bladder cancer	0.000709	0.00886	CbGeAlD
Zafirlukast—CYP3A4—female reproductive system—urinary bladder cancer	0.000655	0.00818	CbGeAlD
Zafirlukast—CYP2D6—female reproductive system—urinary bladder cancer	0.000645	0.00805	CbGeAlD
Zafirlukast—Hypoaesthesia—Fluorouracil—urinary bladder cancer	0.000567	0.00335	CcSEcCtD
Zafirlukast—Rectal haemorrhage—Doxorubicin—urinary bladder cancer	0.000566	0.00335	CcSEcCtD
Zafirlukast—Hyperbilirubinaemia—Doxorubicin—urinary bladder cancer	0.000562	0.00332	CcSEcCtD
Zafirlukast—ABCG2—lymph node—urinary bladder cancer	0.00055	0.00687	CbGeAlD
Zafirlukast—Neuropathy peripheral—Etoposide—urinary bladder cancer	0.000541	0.0032	CcSEcCtD
Zafirlukast—Jaundice—Etoposide—urinary bladder cancer	0.000537	0.00318	CcSEcCtD
Zafirlukast—Influenza like illness—Epirubicin—urinary bladder cancer	0.000537	0.00317	CcSEcCtD
Zafirlukast—Neuropathy—Epirubicin—urinary bladder cancer	0.000519	0.00307	CcSEcCtD
Zafirlukast—Agranulocytosis—Etoposide—urinary bladder cancer	0.000515	0.00304	CcSEcCtD
Zafirlukast—Arthralgia—Thiotepa—urinary bladder cancer	0.000511	0.00302	CcSEcCtD
Zafirlukast—Myalgia—Thiotepa—urinary bladder cancer	0.000511	0.00302	CcSEcCtD
Zafirlukast—Influenza like illness—Doxorubicin—urinary bladder cancer	0.000497	0.00294	CcSEcCtD
Zafirlukast—Hypoaesthesia—Etoposide—urinary bladder cancer	0.000493	0.00291	CcSEcCtD
Zafirlukast—Back pain—Gemcitabine—urinary bladder cancer	0.000488	0.00289	CcSEcCtD
Zafirlukast—Infection—Thiotepa—urinary bladder cancer	0.000486	0.00288	CcSEcCtD
Zafirlukast—Neuropathy—Doxorubicin—urinary bladder cancer	0.00048	0.00284	CcSEcCtD
Zafirlukast—Thrombocytopenia—Thiotepa—urinary bladder cancer	0.000479	0.00283	CcSEcCtD
Zafirlukast—Hepatic failure—Methotrexate—urinary bladder cancer	0.000477	0.00282	CcSEcCtD
Zafirlukast—Ill-defined disorder—Gemcitabine—urinary bladder cancer	0.000468	0.00277	CcSEcCtD
Zafirlukast—Hepatic function abnormal—Epirubicin—urinary bladder cancer	0.000459	0.00271	CcSEcCtD
Zafirlukast—PTGS1—lymph node—urinary bladder cancer	0.000459	0.00573	CbGeAlD
Zafirlukast—Malaise—Gemcitabine—urinary bladder cancer	0.000455	0.00269	CcSEcCtD
Zafirlukast—Hepatic failure—Epirubicin—urinary bladder cancer	0.000446	0.00264	CcSEcCtD
Zafirlukast—Musculoskeletal discomfort—Thiotepa—urinary bladder cancer	0.000446	0.00264	CcSEcCtD
Zafirlukast—Ill-defined disorder—Cisplatin—urinary bladder cancer	0.000436	0.00258	CcSEcCtD
Zafirlukast—Dyspepsia—Thiotepa—urinary bladder cancer	0.000431	0.00255	CcSEcCtD
Zafirlukast—Arthralgia—Gemcitabine—urinary bladder cancer	0.00043	0.00254	CcSEcCtD
Zafirlukast—Myalgia—Gemcitabine—urinary bladder cancer	0.00043	0.00254	CcSEcCtD
Zafirlukast—Hepatic function abnormal—Doxorubicin—urinary bladder cancer	0.000425	0.00251	CcSEcCtD
Zafirlukast—Discomfort—Gemcitabine—urinary bladder cancer	0.000424	0.00251	CcSEcCtD
Zafirlukast—Malaise—Cisplatin—urinary bladder cancer	0.000424	0.00251	CcSEcCtD
Zafirlukast—Gastrointestinal disorder—Thiotepa—urinary bladder cancer	0.000423	0.0025	CcSEcCtD
Zafirlukast—Myalgia—Fluorouracil—urinary bladder cancer	0.000422	0.0025	CcSEcCtD
Zafirlukast—Fatigue—Thiotepa—urinary bladder cancer	0.000422	0.0025	CcSEcCtD
Zafirlukast—Dermatitis bullous—Epirubicin—urinary bladder cancer	0.00042	0.00248	CcSEcCtD
Zafirlukast—Pain—Thiotepa—urinary bladder cancer	0.000419	0.00248	CcSEcCtD
Zafirlukast—Discomfort—Fluorouracil—urinary bladder cancer	0.000417	0.00247	CcSEcCtD
Zafirlukast—Back pain—Etoposide—urinary bladder cancer	0.000417	0.00247	CcSEcCtD
Zafirlukast—Hepatic failure—Doxorubicin—urinary bladder cancer	0.000413	0.00244	CcSEcCtD
Zafirlukast—Oedema—Gemcitabine—urinary bladder cancer	0.000412	0.00244	CcSEcCtD
Zafirlukast—Infection—Gemcitabine—urinary bladder cancer	0.000409	0.00242	CcSEcCtD
Zafirlukast—Oedema—Fluorouracil—urinary bladder cancer	0.000405	0.00239	CcSEcCtD
Zafirlukast—Feeling abnormal—Thiotepa—urinary bladder cancer	0.000403	0.00239	CcSEcCtD
Zafirlukast—Thrombocytopenia—Gemcitabine—urinary bladder cancer	0.000403	0.00238	CcSEcCtD
Zafirlukast—Infection—Fluorouracil—urinary bladder cancer	0.000402	0.00238	CcSEcCtD
Zafirlukast—Myalgia—Cisplatin—urinary bladder cancer	0.0004	0.00237	CcSEcCtD
Zafirlukast—Gastrointestinal pain—Thiotepa—urinary bladder cancer	0.0004	0.00237	CcSEcCtD
Zafirlukast—Ill-defined disorder—Etoposide—urinary bladder cancer	0.0004	0.00236	CcSEcCtD
Zafirlukast—Thrombocytopenia—Fluorouracil—urinary bladder cancer	0.000396	0.00234	CcSEcCtD
Zafirlukast—Liver function test abnormal—Methotrexate—urinary bladder cancer	0.000396	0.00234	CcSEcCtD
Zafirlukast—Discomfort—Cisplatin—urinary bladder cancer	0.000396	0.00234	CcSEcCtD
Zafirlukast—Urticaria—Thiotepa—urinary bladder cancer	0.000389	0.0023	CcSEcCtD
Zafirlukast—Malaise—Etoposide—urinary bladder cancer	0.000389	0.0023	CcSEcCtD
Zafirlukast—Dermatitis bullous—Doxorubicin—urinary bladder cancer	0.000388	0.0023	CcSEcCtD
Zafirlukast—Abdominal pain—Thiotepa—urinary bladder cancer	0.000387	0.00229	CcSEcCtD
Zafirlukast—Body temperature increased—Thiotepa—urinary bladder cancer	0.000387	0.00229	CcSEcCtD
Zafirlukast—Oedema—Cisplatin—urinary bladder cancer	0.000384	0.00227	CcSEcCtD
Zafirlukast—Infection—Cisplatin—urinary bladder cancer	0.000381	0.00226	CcSEcCtD
Zafirlukast—Thrombocytopenia—Cisplatin—urinary bladder cancer	0.000376	0.00222	CcSEcCtD
Zafirlukast—Musculoskeletal discomfort—Gemcitabine—urinary bladder cancer	0.000375	0.00222	CcSEcCtD
Zafirlukast—Insomnia—Gemcitabine—urinary bladder cancer	0.000373	0.0022	CcSEcCtD
Zafirlukast—Liver function test abnormal—Epirubicin—urinary bladder cancer	0.00037	0.00219	CcSEcCtD
Zafirlukast—Musculoskeletal discomfort—Fluorouracil—urinary bladder cancer	0.000369	0.00218	CcSEcCtD
Zafirlukast—Eosinophilia—Methotrexate—urinary bladder cancer	0.000367	0.00217	CcSEcCtD
Zafirlukast—Insomnia—Fluorouracil—urinary bladder cancer	0.000366	0.00217	CcSEcCtD
Zafirlukast—Discomfort—Etoposide—urinary bladder cancer	0.000362	0.00214	CcSEcCtD
Zafirlukast—Hypersensitivity—Thiotepa—urinary bladder cancer	0.000361	0.00213	CcSEcCtD
Zafirlukast—Dyspepsia—Fluorouracil—urinary bladder cancer	0.000356	0.00211	CcSEcCtD
Zafirlukast—Gastrointestinal disorder—Gemcitabine—urinary bladder cancer	0.000356	0.0021	CcSEcCtD
Zafirlukast—Abdominal discomfort—Methotrexate—urinary bladder cancer	0.000355	0.0021	CcSEcCtD
Zafirlukast—Fatigue—Gemcitabine—urinary bladder cancer	0.000355	0.0021	CcSEcCtD
Zafirlukast—Pain—Gemcitabine—urinary bladder cancer	0.000352	0.00208	CcSEcCtD
Zafirlukast—Asthenia—Thiotepa—urinary bladder cancer	0.000351	0.00208	CcSEcCtD
Zafirlukast—Musculoskeletal discomfort—Cisplatin—urinary bladder cancer	0.00035	0.00207	CcSEcCtD
Zafirlukast—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	0.00035	0.00207	CcSEcCtD
Zafirlukast—Infection—Etoposide—urinary bladder cancer	0.000349	0.00207	CcSEcCtD
Zafirlukast—Neutropenia—Methotrexate—urinary bladder cancer	0.000346	0.00205	CcSEcCtD
Zafirlukast—Pruritus—Thiotepa—urinary bladder cancer	0.000346	0.00205	CcSEcCtD
Zafirlukast—Pain—Fluorouracil—urinary bladder cancer	0.000346	0.00205	CcSEcCtD
Zafirlukast—Thrombocytopenia—Etoposide—urinary bladder cancer	0.000344	0.00204	CcSEcCtD
Zafirlukast—Eosinophilia—Epirubicin—urinary bladder cancer	0.000343	0.00203	CcSEcCtD
Zafirlukast—Liver function test abnormal—Doxorubicin—urinary bladder cancer	0.000343	0.00203	CcSEcCtD
Zafirlukast—Feeling abnormal—Gemcitabine—urinary bladder cancer	0.000339	0.00201	CcSEcCtD
Zafirlukast—Diarrhoea—Thiotepa—urinary bladder cancer	0.000335	0.00198	CcSEcCtD
Zafirlukast—Feeling abnormal—Fluorouracil—urinary bladder cancer	0.000334	0.00197	CcSEcCtD
Zafirlukast—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.000331	0.00196	CcSEcCtD
Zafirlukast—Pain—Cisplatin—urinary bladder cancer	0.000328	0.00194	CcSEcCtD
Zafirlukast—Body temperature increased—Gemcitabine—urinary bladder cancer	0.000326	0.00193	CcSEcCtD
Zafirlukast—Neutropenia—Epirubicin—urinary bladder cancer	0.000324	0.00192	CcSEcCtD
Zafirlukast—Dizziness—Thiotepa—urinary bladder cancer	0.000324	0.00191	CcSEcCtD
Zafirlukast—Urticaria—Fluorouracil—urinary bladder cancer	0.000322	0.0019	CcSEcCtD
Zafirlukast—Body temperature increased—Fluorouracil—urinary bladder cancer	0.00032	0.00189	CcSEcCtD
Zafirlukast—Eosinophilia—Doxorubicin—urinary bladder cancer	0.000318	0.00188	CcSEcCtD
Zafirlukast—Feeling abnormal—Cisplatin—urinary bladder cancer	0.000316	0.00187	CcSEcCtD
Zafirlukast—Vomiting—Thiotepa—urinary bladder cancer	0.000311	0.00184	CcSEcCtD
Zafirlukast—Rash—Thiotepa—urinary bladder cancer	0.000309	0.00183	CcSEcCtD
Zafirlukast—Dermatitis—Thiotepa—urinary bladder cancer	0.000308	0.00182	CcSEcCtD
Zafirlukast—Agranulocytosis—Methotrexate—urinary bladder cancer	0.000308	0.00182	CcSEcCtD
Zafirlukast—Headache—Thiotepa—urinary bladder cancer	0.000307	0.00181	CcSEcCtD
Zafirlukast—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.000304	0.0018	CcSEcCtD
Zafirlukast—Body temperature increased—Cisplatin—urinary bladder cancer	0.000303	0.00179	CcSEcCtD
Zafirlukast—Fatigue—Etoposide—urinary bladder cancer	0.000303	0.00179	CcSEcCtD
Zafirlukast—Neuropathy peripheral—Epirubicin—urinary bladder cancer	0.000303	0.00179	CcSEcCtD
Zafirlukast—Jaundice—Epirubicin—urinary bladder cancer	0.000301	0.00178	CcSEcCtD
Zafirlukast—Pain—Etoposide—urinary bladder cancer	0.000301	0.00178	CcSEcCtD
Zafirlukast—Neutropenia—Doxorubicin—urinary bladder cancer	0.0003	0.00177	CcSEcCtD
Zafirlukast—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.000298	0.00176	CcSEcCtD
Zafirlukast—Haemoglobin—Methotrexate—urinary bladder cancer	0.000298	0.00176	CcSEcCtD
Zafirlukast—Haemorrhage—Methotrexate—urinary bladder cancer	0.000297	0.00175	CcSEcCtD
Zafirlukast—Hepatitis—Methotrexate—urinary bladder cancer	0.000297	0.00175	CcSEcCtD
Zafirlukast—Asthenia—Gemcitabine—urinary bladder cancer	0.000295	0.00175	CcSEcCtD
Zafirlukast—Pruritus—Gemcitabine—urinary bladder cancer	0.000291	0.00172	CcSEcCtD
Zafirlukast—Nausea—Thiotepa—urinary bladder cancer	0.000291	0.00172	CcSEcCtD
Zafirlukast—Sinusitis—Epirubicin—urinary bladder cancer	0.00029	0.00171	CcSEcCtD
Zafirlukast—Feeling abnormal—Etoposide—urinary bladder cancer	0.00029	0.00171	CcSEcCtD
Zafirlukast—Agranulocytosis—Epirubicin—urinary bladder cancer	0.000288	0.00171	CcSEcCtD
Zafirlukast—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000288	0.0017	CcSEcCtD
Zafirlukast—Pruritus—Fluorouracil—urinary bladder cancer	0.000286	0.00169	CcSEcCtD
Zafirlukast—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000283	0.00167	CcSEcCtD
Zafirlukast—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000282	0.00167	CcSEcCtD
Zafirlukast—Neuropathy peripheral—Doxorubicin—urinary bladder cancer	0.00028	0.00166	CcSEcCtD
Zafirlukast—Urticaria—Etoposide—urinary bladder cancer	0.000279	0.00165	CcSEcCtD
Zafirlukast—Haemoglobin—Epirubicin—urinary bladder cancer	0.000279	0.00165	CcSEcCtD
Zafirlukast—Jaundice—Doxorubicin—urinary bladder cancer	0.000279	0.00165	CcSEcCtD
Zafirlukast—Abdominal pain—Etoposide—urinary bladder cancer	0.000278	0.00164	CcSEcCtD
Zafirlukast—Body temperature increased—Etoposide—urinary bladder cancer	0.000278	0.00164	CcSEcCtD
Zafirlukast—Haemorrhage—Epirubicin—urinary bladder cancer	0.000277	0.00164	CcSEcCtD
Zafirlukast—Hepatitis—Epirubicin—urinary bladder cancer	0.000277	0.00164	CcSEcCtD
Zafirlukast—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000277	0.00164	CcSEcCtD
Zafirlukast—Hypoaesthesia—Epirubicin—urinary bladder cancer	0.000276	0.00163	CcSEcCtD
Zafirlukast—Asthenia—Cisplatin—urinary bladder cancer	0.000275	0.00163	CcSEcCtD
Zafirlukast—Sinusitis—Doxorubicin—urinary bladder cancer	0.000268	0.00159	CcSEcCtD
Zafirlukast—Dizziness—Fluorouracil—urinary bladder cancer	0.000268	0.00158	CcSEcCtD
Zafirlukast—Agranulocytosis—Doxorubicin—urinary bladder cancer	0.000267	0.00158	CcSEcCtD
Zafirlukast—Diarrhoea—Cisplatin—urinary bladder cancer	0.000263	0.00155	CcSEcCtD
Zafirlukast—Vomiting—Gemcitabine—urinary bladder cancer	0.000262	0.00155	CcSEcCtD
Zafirlukast—Rash—Gemcitabine—urinary bladder cancer	0.00026	0.00154	CcSEcCtD
Zafirlukast—Dermatitis—Gemcitabine—urinary bladder cancer	0.000259	0.00153	CcSEcCtD
Zafirlukast—Hypersensitivity—Etoposide—urinary bladder cancer	0.000259	0.00153	CcSEcCtD
Zafirlukast—Haemoglobin—Doxorubicin—urinary bladder cancer	0.000258	0.00153	CcSEcCtD
Zafirlukast—Headache—Gemcitabine—urinary bladder cancer	0.000258	0.00153	CcSEcCtD
Zafirlukast—Vomiting—Fluorouracil—urinary bladder cancer	0.000257	0.00152	CcSEcCtD
Zafirlukast—Haemorrhage—Doxorubicin—urinary bladder cancer	0.000257	0.00152	CcSEcCtD
Zafirlukast—Hepatitis—Doxorubicin—urinary bladder cancer	0.000257	0.00152	CcSEcCtD
Zafirlukast—Hypoaesthesia—Doxorubicin—urinary bladder cancer	0.000255	0.00151	CcSEcCtD
Zafirlukast—Rash—Fluorouracil—urinary bladder cancer	0.000255	0.00151	CcSEcCtD
Zafirlukast—Dermatitis—Fluorouracil—urinary bladder cancer	0.000255	0.00151	CcSEcCtD
Zafirlukast—Headache—Fluorouracil—urinary bladder cancer	0.000254	0.0015	CcSEcCtD
Zafirlukast—Asthenia—Etoposide—urinary bladder cancer	0.000252	0.00149	CcSEcCtD
Zafirlukast—Back pain—Methotrexate—urinary bladder cancer	0.00025	0.00148	CcSEcCtD
Zafirlukast—Pruritus—Etoposide—urinary bladder cancer	0.000249	0.00147	CcSEcCtD
Zafirlukast—Nausea—Gemcitabine—urinary bladder cancer	0.000245	0.00145	CcSEcCtD
Zafirlukast—Vomiting—Cisplatin—urinary bladder cancer	0.000244	0.00144	CcSEcCtD
Zafirlukast—Rash—Cisplatin—urinary bladder cancer	0.000242	0.00143	CcSEcCtD
Zafirlukast—Dermatitis—Cisplatin—urinary bladder cancer	0.000242	0.00143	CcSEcCtD
Zafirlukast—Diarrhoea—Etoposide—urinary bladder cancer	0.000241	0.00142	CcSEcCtD
Zafirlukast—Nausea—Fluorouracil—urinary bladder cancer	0.000241	0.00142	CcSEcCtD
Zafirlukast—Ill-defined disorder—Methotrexate—urinary bladder cancer	0.000239	0.00142	CcSEcCtD
Zafirlukast—Back pain—Epirubicin—urinary bladder cancer	0.000234	0.00138	CcSEcCtD
Zafirlukast—Malaise—Methotrexate—urinary bladder cancer	0.000233	0.00138	CcSEcCtD
Zafirlukast—Dizziness—Etoposide—urinary bladder cancer	0.000233	0.00138	CcSEcCtD
Zafirlukast—Nausea—Cisplatin—urinary bladder cancer	0.000228	0.00135	CcSEcCtD
Zafirlukast—Ill-defined disorder—Epirubicin—urinary bladder cancer	0.000224	0.00133	CcSEcCtD
Zafirlukast—Vomiting—Etoposide—urinary bladder cancer	0.000224	0.00132	CcSEcCtD
Zafirlukast—Rash—Etoposide—urinary bladder cancer	0.000222	0.00131	CcSEcCtD
Zafirlukast—Dermatitis—Etoposide—urinary bladder cancer	0.000222	0.00131	CcSEcCtD
Zafirlukast—Headache—Etoposide—urinary bladder cancer	0.00022	0.0013	CcSEcCtD
Zafirlukast—Myalgia—Methotrexate—urinary bladder cancer	0.00022	0.0013	CcSEcCtD
Zafirlukast—Arthralgia—Methotrexate—urinary bladder cancer	0.00022	0.0013	CcSEcCtD
Zafirlukast—Malaise—Epirubicin—urinary bladder cancer	0.000218	0.00129	CcSEcCtD
Zafirlukast—Discomfort—Methotrexate—urinary bladder cancer	0.000217	0.00128	CcSEcCtD
Zafirlukast—Back pain—Doxorubicin—urinary bladder cancer	0.000216	0.00128	CcSEcCtD
Zafirlukast—Infection—Methotrexate—urinary bladder cancer	0.000209	0.00124	CcSEcCtD
Zafirlukast—Nausea—Etoposide—urinary bladder cancer	0.000209	0.00124	CcSEcCtD
Zafirlukast—Ill-defined disorder—Doxorubicin—urinary bladder cancer	0.000207	0.00123	CcSEcCtD
Zafirlukast—Thrombocytopenia—Methotrexate—urinary bladder cancer	0.000206	0.00122	CcSEcCtD
Zafirlukast—Myalgia—Epirubicin—urinary bladder cancer	0.000206	0.00122	CcSEcCtD
Zafirlukast—Arthralgia—Epirubicin—urinary bladder cancer	0.000206	0.00122	CcSEcCtD
Zafirlukast—Discomfort—Epirubicin—urinary bladder cancer	0.000203	0.0012	CcSEcCtD
Zafirlukast—Malaise—Doxorubicin—urinary bladder cancer	0.000202	0.00119	CcSEcCtD
Zafirlukast—Oedema—Epirubicin—urinary bladder cancer	0.000197	0.00117	CcSEcCtD
Zafirlukast—Infection—Epirubicin—urinary bladder cancer	0.000196	0.00116	CcSEcCtD
Zafirlukast—Thrombocytopenia—Epirubicin—urinary bladder cancer	0.000193	0.00114	CcSEcCtD
Zafirlukast—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000192	0.00113	CcSEcCtD
Zafirlukast—Insomnia—Methotrexate—urinary bladder cancer	0.000191	0.00113	CcSEcCtD
Zafirlukast—Myalgia—Doxorubicin—urinary bladder cancer	0.00019	0.00113	CcSEcCtD
Zafirlukast—Arthralgia—Doxorubicin—urinary bladder cancer	0.00019	0.00113	CcSEcCtD
Zafirlukast—Discomfort—Doxorubicin—urinary bladder cancer	0.000188	0.00111	CcSEcCtD
Zafirlukast—Dyspepsia—Methotrexate—urinary bladder cancer	0.000185	0.0011	CcSEcCtD
Zafirlukast—Oedema—Doxorubicin—urinary bladder cancer	0.000182	0.00108	CcSEcCtD
Zafirlukast—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000182	0.00108	CcSEcCtD
Zafirlukast—Fatigue—Methotrexate—urinary bladder cancer	0.000182	0.00107	CcSEcCtD
Zafirlukast—Infection—Doxorubicin—urinary bladder cancer	0.000181	0.00107	CcSEcCtD
Zafirlukast—Pain—Methotrexate—urinary bladder cancer	0.00018	0.00107	CcSEcCtD
Zafirlukast—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.00018	0.00106	CcSEcCtD
Zafirlukast—Thrombocytopenia—Doxorubicin—urinary bladder cancer	0.000179	0.00106	CcSEcCtD
Zafirlukast—Insomnia—Epirubicin—urinary bladder cancer	0.000178	0.00105	CcSEcCtD
Zafirlukast—Feeling abnormal—Methotrexate—urinary bladder cancer	0.000174	0.00103	CcSEcCtD
Zafirlukast—Dyspepsia—Epirubicin—urinary bladder cancer	0.000174	0.00103	CcSEcCtD
Zafirlukast—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000172	0.00102	CcSEcCtD
Zafirlukast—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.00017	0.00101	CcSEcCtD
Zafirlukast—Fatigue—Epirubicin—urinary bladder cancer	0.00017	0.00101	CcSEcCtD
Zafirlukast—Pain—Epirubicin—urinary bladder cancer	0.000169	0.000997	CcSEcCtD
Zafirlukast—Urticaria—Methotrexate—urinary bladder cancer	0.000167	0.00099	CcSEcCtD
Zafirlukast—Abdominal pain—Methotrexate—urinary bladder cancer	0.000167	0.000985	CcSEcCtD
Zafirlukast—Body temperature increased—Methotrexate—urinary bladder cancer	0.000167	0.000985	CcSEcCtD
Zafirlukast—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.000166	0.000983	CcSEcCtD
Zafirlukast—Insomnia—Doxorubicin—urinary bladder cancer	0.000165	0.000976	CcSEcCtD
Zafirlukast—Feeling abnormal—Epirubicin—urinary bladder cancer	0.000162	0.000961	CcSEcCtD
Zafirlukast—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000161	0.000953	CcSEcCtD
Zafirlukast—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000161	0.00095	CcSEcCtD
Zafirlukast—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000157	0.000931	CcSEcCtD
Zafirlukast—Fatigue—Doxorubicin—urinary bladder cancer	0.000157	0.00093	CcSEcCtD
Zafirlukast—Urticaria—Epirubicin—urinary bladder cancer	0.000157	0.000926	CcSEcCtD
Zafirlukast—Pain—Doxorubicin—urinary bladder cancer	0.000156	0.000922	CcSEcCtD
Zafirlukast—Body temperature increased—Epirubicin—urinary bladder cancer	0.000156	0.000922	CcSEcCtD
Zafirlukast—Abdominal pain—Epirubicin—urinary bladder cancer	0.000156	0.000922	CcSEcCtD
Zafirlukast—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000155	0.000918	CcSEcCtD
Zafirlukast—Asthenia—Methotrexate—urinary bladder cancer	0.000151	0.000894	CcSEcCtD
Zafirlukast—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.00015	0.000889	CcSEcCtD
Zafirlukast—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000149	0.000882	CcSEcCtD
Zafirlukast—Pruritus—Methotrexate—urinary bladder cancer	0.000149	0.000881	CcSEcCtD
Zafirlukast—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000145	0.000859	CcSEcCtD
Zafirlukast—Urticaria—Doxorubicin—urinary bladder cancer	0.000145	0.000857	CcSEcCtD
Zafirlukast—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000144	0.000853	CcSEcCtD
Zafirlukast—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000144	0.000853	CcSEcCtD
Zafirlukast—Diarrhoea—Methotrexate—urinary bladder cancer	0.000144	0.000852	CcSEcCtD
Zafirlukast—Asthenia—Epirubicin—urinary bladder cancer	0.000141	0.000836	CcSEcCtD
Zafirlukast—Pruritus—Epirubicin—urinary bladder cancer	0.000139	0.000825	CcSEcCtD
Zafirlukast—Dizziness—Methotrexate—urinary bladder cancer	0.000139	0.000824	CcSEcCtD
Zafirlukast—Diarrhoea—Epirubicin—urinary bladder cancer	0.000135	0.000798	CcSEcCtD
Zafirlukast—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000134	0.000795	CcSEcCtD
Zafirlukast—Vomiting—Methotrexate—urinary bladder cancer	0.000134	0.000792	CcSEcCtD
Zafirlukast—Rash—Methotrexate—urinary bladder cancer	0.000133	0.000785	CcSEcCtD
Zafirlukast—Dermatitis—Methotrexate—urinary bladder cancer	0.000133	0.000785	CcSEcCtD
Zafirlukast—Headache—Methotrexate—urinary bladder cancer	0.000132	0.00078	CcSEcCtD
Zafirlukast—Asthenia—Doxorubicin—urinary bladder cancer	0.000131	0.000774	CcSEcCtD
Zafirlukast—Dizziness—Epirubicin—urinary bladder cancer	0.00013	0.000771	CcSEcCtD
Zafirlukast—Pruritus—Doxorubicin—urinary bladder cancer	0.000129	0.000763	CcSEcCtD
Zafirlukast—Vomiting—Epirubicin—urinary bladder cancer	0.000125	0.000741	CcSEcCtD
Zafirlukast—Nausea—Methotrexate—urinary bladder cancer	0.000125	0.00074	CcSEcCtD
Zafirlukast—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000125	0.000738	CcSEcCtD
Zafirlukast—Rash—Epirubicin—urinary bladder cancer	0.000124	0.000735	CcSEcCtD
Zafirlukast—Dermatitis—Epirubicin—urinary bladder cancer	0.000124	0.000734	CcSEcCtD
Zafirlukast—Headache—Epirubicin—urinary bladder cancer	0.000123	0.00073	CcSEcCtD
Zafirlukast—Dizziness—Doxorubicin—urinary bladder cancer	0.000121	0.000713	CcSEcCtD
Zafirlukast—Nausea—Epirubicin—urinary bladder cancer	0.000117	0.000692	CcSEcCtD
Zafirlukast—Vomiting—Doxorubicin—urinary bladder cancer	0.000116	0.000686	CcSEcCtD
Zafirlukast—Rash—Doxorubicin—urinary bladder cancer	0.000115	0.00068	CcSEcCtD
Zafirlukast—Dermatitis—Doxorubicin—urinary bladder cancer	0.000115	0.00068	CcSEcCtD
Zafirlukast—Headache—Doxorubicin—urinary bladder cancer	0.000114	0.000676	CcSEcCtD
Zafirlukast—Nausea—Doxorubicin—urinary bladder cancer	0.000108	0.000641	CcSEcCtD
Zafirlukast—CYP1A2—Metabolism—GSTZ1—urinary bladder cancer	3.85e-05	0.000342	CbGpPWpGaD
Zafirlukast—PTGS1—Metabolism—RRM2—urinary bladder cancer	3.84e-05	0.000341	CbGpPWpGaD
Zafirlukast—CYSLTR1—Signaling Pathways—CREBBP—urinary bladder cancer	3.77e-05	0.000334	CbGpPWpGaD
Zafirlukast—CYSLTR1—Signaling Pathways—IGF1—urinary bladder cancer	3.72e-05	0.00033	CbGpPWpGaD
Zafirlukast—ABCG2—Metabolism—HPGDS—urinary bladder cancer	3.7e-05	0.000329	CbGpPWpGaD
Zafirlukast—ABCG2—Metabolism—ENO2—urinary bladder cancer	3.7e-05	0.000329	CbGpPWpGaD
Zafirlukast—CYSLTR1—Signaling by GPCR—EGFR—urinary bladder cancer	3.7e-05	0.000328	CbGpPWpGaD
Zafirlukast—CYSLTR2—Signaling Pathways—EP300—urinary bladder cancer	3.7e-05	0.000328	CbGpPWpGaD
Zafirlukast—CYP2E1—Metabolism—TYMP—urinary bladder cancer	3.68e-05	0.000326	CbGpPWpGaD
Zafirlukast—CYP1A2—Metabolism—GSTO2—urinary bladder cancer	3.65e-05	0.000324	CbGpPWpGaD
Zafirlukast—CYP1A2—Metabolism—NAT1—urinary bladder cancer	3.65e-05	0.000324	CbGpPWpGaD
Zafirlukast—CYP2C19—Metabolism—SLC19A1—urinary bladder cancer	3.64e-05	0.000323	CbGpPWpGaD
Zafirlukast—CYSLTR2—Signaling Pathways—SRC—urinary bladder cancer	3.6e-05	0.000319	CbGpPWpGaD
Zafirlukast—ABCG2—Metabolism—GSTT1—urinary bladder cancer	3.59e-05	0.000319	CbGpPWpGaD
Zafirlukast—CYP1A2—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	3.59e-05	0.000319	CbGpPWpGaD
Zafirlukast—PTGS1—Metabolism—ENO2—urinary bladder cancer	3.56e-05	0.000316	CbGpPWpGaD
Zafirlukast—PTGS1—Metabolism—HPGDS—urinary bladder cancer	3.56e-05	0.000316	CbGpPWpGaD
Zafirlukast—CYP2C19—Metabolism—PRSS3—urinary bladder cancer	3.55e-05	0.000315	CbGpPWpGaD
Zafirlukast—CYP2D6—Metabolism—CYP4B1—urinary bladder cancer	3.55e-05	0.000315	CbGpPWpGaD
Zafirlukast—PTGS1—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	3.54e-05	0.000314	CbGpPWpGaD
Zafirlukast—CYP2C9—Metabolism—CYP4B1—urinary bladder cancer	3.52e-05	0.000312	CbGpPWpGaD
Zafirlukast—CYSLTR1—Signaling by GPCR—KRAS—urinary bladder cancer	3.5e-05	0.00031	CbGpPWpGaD
Zafirlukast—PTGS1—Metabolism—GSTT1—urinary bladder cancer	3.45e-05	0.000306	CbGpPWpGaD
Zafirlukast—CYSLTR1—Signaling Pathways—RHOA—urinary bladder cancer	3.41e-05	0.000302	CbGpPWpGaD
Zafirlukast—PTGS1—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	3.4e-05	0.000302	CbGpPWpGaD
Zafirlukast—ABCG2—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	3.36e-05	0.000299	CbGpPWpGaD
Zafirlukast—CYP2D6—Metabolism—SLC19A1—urinary bladder cancer	3.35e-05	0.000297	CbGpPWpGaD
Zafirlukast—CYP1A2—Metabolism—UGT2B7—urinary bladder cancer	3.34e-05	0.000296	CbGpPWpGaD
Zafirlukast—CYP2E1—Metabolism—NAT2—urinary bladder cancer	3.33e-05	0.000295	CbGpPWpGaD
Zafirlukast—CYP2C9—Metabolism—SLC19A1—urinary bladder cancer	3.32e-05	0.000295	CbGpPWpGaD
Zafirlukast—CYP2D6—Metabolism—PRSS3—urinary bladder cancer	3.27e-05	0.00029	CbGpPWpGaD
Zafirlukast—CYP2C9—Metabolism—PRSS3—urinary bladder cancer	3.24e-05	0.000287	CbGpPWpGaD
Zafirlukast—CYSLTR2—Signaling Pathways—MYC—urinary bladder cancer	3.23e-05	0.000286	CbGpPWpGaD
Zafirlukast—CYP2C8—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	3.19e-05	0.000283	CbGpPWpGaD
Zafirlukast—CYP2C8—Metabolism—TYMP—urinary bladder cancer	3.18e-05	0.000282	CbGpPWpGaD
Zafirlukast—CYSLTR2—Signaling Pathways—EGFR—urinary bladder cancer	3.15e-05	0.00028	CbGpPWpGaD
Zafirlukast—CYSLTR1—Signaling Pathways—ERBB2—urinary bladder cancer	3.15e-05	0.00028	CbGpPWpGaD
Zafirlukast—CYP2C8—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	3.05e-05	0.000271	CbGpPWpGaD
Zafirlukast—CYP1A2—Metabolism—CYP4B1—urinary bladder cancer	3.01e-05	0.000267	CbGpPWpGaD
Zafirlukast—CYSLTR1—Signaling Pathways—CXCL8—urinary bladder cancer	2.99e-05	0.000265	CbGpPWpGaD
Zafirlukast—ABCG2—Metabolism—NQO1—urinary bladder cancer	2.99e-05	0.000265	CbGpPWpGaD
Zafirlukast—CYSLTR2—Signaling Pathways—KRAS—urinary bladder cancer	2.98e-05	0.000264	CbGpPWpGaD
Zafirlukast—CYSLTR1—Signaling by GPCR—HRAS—urinary bladder cancer	2.97e-05	0.000264	CbGpPWpGaD
Zafirlukast—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	2.97e-05	0.000264	CbGpPWpGaD
Zafirlukast—CYP2C8—Metabolism—NAT2—urinary bladder cancer	2.88e-05	0.000255	CbGpPWpGaD
Zafirlukast—CYP2E1—Metabolism—RRM2—urinary bladder cancer	2.87e-05	0.000255	CbGpPWpGaD
Zafirlukast—PTGS1—Metabolism—NQO1—urinary bladder cancer	2.87e-05	0.000255	CbGpPWpGaD
Zafirlukast—CYSLTR1—Signaling Pathways—IL2—urinary bladder cancer	2.86e-05	0.000254	CbGpPWpGaD
Zafirlukast—CYP2C19—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	2.85e-05	0.000253	CbGpPWpGaD
Zafirlukast—CYP1A2—Metabolism—SLC19A1—urinary bladder cancer	2.84e-05	0.000252	CbGpPWpGaD
Zafirlukast—CYP2C19—Metabolism—TYMP—urinary bladder cancer	2.84e-05	0.000252	CbGpPWpGaD
Zafirlukast—CYP3A4—Metabolism—NAT1—urinary bladder cancer	2.82e-05	0.00025	CbGpPWpGaD
Zafirlukast—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	2.82e-05	0.00025	CbGpPWpGaD
Zafirlukast—CYSLTR1—Signaling Pathways—CCND1—urinary bladder cancer	2.79e-05	0.000247	CbGpPWpGaD
Zafirlukast—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	2.78e-05	0.000247	CbGpPWpGaD
Zafirlukast—CYP1A2—Metabolism—PRSS3—urinary bladder cancer	2.77e-05	0.000245	CbGpPWpGaD
Zafirlukast—CYP2C19—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	2.73e-05	0.000242	CbGpPWpGaD
Zafirlukast—CYSLTR1—Signaling Pathways—MMP9—urinary bladder cancer	2.71e-05	0.00024	CbGpPWpGaD
Zafirlukast—CYSLTR1—Signaling Pathways—CDKN1A—urinary bladder cancer	2.7e-05	0.000239	CbGpPWpGaD
Zafirlukast—CYSLTR1—Signaling Pathways—PTEN—urinary bladder cancer	2.69e-05	0.000239	CbGpPWpGaD
Zafirlukast—CYP2E1—Metabolism—ENO2—urinary bladder cancer	2.66e-05	0.000236	CbGpPWpGaD
Zafirlukast—CYP2E1—Metabolism—HPGDS—urinary bladder cancer	2.66e-05	0.000236	CbGpPWpGaD
Zafirlukast—CYSLTR2—Signaling Pathways—TP53—urinary bladder cancer	2.65e-05	0.000235	CbGpPWpGaD
Zafirlukast—CYP2D6—Metabolism—TYMP—urinary bladder cancer	2.61e-05	0.000232	CbGpPWpGaD
Zafirlukast—CYP2C9—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	2.6e-05	0.00023	CbGpPWpGaD
Zafirlukast—CYP2C9—Metabolism—TYMP—urinary bladder cancer	2.59e-05	0.00023	CbGpPWpGaD
Zafirlukast—CYP2E1—Metabolism—GSTT1—urinary bladder cancer	2.58e-05	0.000229	CbGpPWpGaD
Zafirlukast—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	2.58e-05	0.000229	CbGpPWpGaD
Zafirlukast—CYP2C19—Metabolism—NAT2—urinary bladder cancer	2.57e-05	0.000228	CbGpPWpGaD
Zafirlukast—CYSLTR1—Signaling Pathways—EP300—urinary bladder cancer	2.57e-05	0.000228	CbGpPWpGaD
Zafirlukast—CYSLTR2—Signaling Pathways—HRAS—urinary bladder cancer	2.53e-05	0.000225	CbGpPWpGaD
Zafirlukast—CYSLTR1—Signaling Pathways—SRC—urinary bladder cancer	2.49e-05	0.000221	CbGpPWpGaD
Zafirlukast—ABCG2—Metabolism—GSTP1—urinary bladder cancer	2.49e-05	0.000221	CbGpPWpGaD
Zafirlukast—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	2.49e-05	0.000221	CbGpPWpGaD
Zafirlukast—CYP2C8—Metabolism—RRM2—urinary bladder cancer	2.48e-05	0.00022	CbGpPWpGaD
Zafirlukast—PTGS1—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	2.43e-05	0.000215	CbGpPWpGaD
Zafirlukast—PTGS1—Metabolism—GSTP1—urinary bladder cancer	2.39e-05	0.000212	CbGpPWpGaD
Zafirlukast—CYP2D6—Metabolism—NAT2—urinary bladder cancer	2.36e-05	0.000209	CbGpPWpGaD
Zafirlukast—CYP2C9—Metabolism—NAT2—urinary bladder cancer	2.34e-05	0.000208	CbGpPWpGaD
Zafirlukast—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	2.32e-05	0.000206	CbGpPWpGaD
Zafirlukast—ABCG2—Metabolism—TYMS—urinary bladder cancer	2.32e-05	0.000205	CbGpPWpGaD
Zafirlukast—PTGS1—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	2.32e-05	0.000205	CbGpPWpGaD
Zafirlukast—CYP2C8—Metabolism—HPGDS—urinary bladder cancer	2.3e-05	0.000204	CbGpPWpGaD
Zafirlukast—CYP2C8—Metabolism—ENO2—urinary bladder cancer	2.3e-05	0.000204	CbGpPWpGaD
Zafirlukast—ABCG2—Metabolism—GSTM1—urinary bladder cancer	2.29e-05	0.000203	CbGpPWpGaD
Zafirlukast—ABCG2—Metabolism—NCOR1—urinary bladder cancer	2.29e-05	0.000203	CbGpPWpGaD
Zafirlukast—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	2.29e-05	0.000203	CbGpPWpGaD
Zafirlukast—CYSLTR1—Signaling Pathways—MYC—urinary bladder cancer	2.24e-05	0.000198	CbGpPWpGaD
Zafirlukast—CYP2C8—Metabolism—GSTT1—urinary bladder cancer	2.23e-05	0.000198	CbGpPWpGaD
Zafirlukast—PTGS1—Metabolism—TYMS—urinary bladder cancer	2.22e-05	0.000197	CbGpPWpGaD
Zafirlukast—CYP1A2—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	2.22e-05	0.000197	CbGpPWpGaD
Zafirlukast—CYP2C19—Metabolism—RRM2—urinary bladder cancer	2.22e-05	0.000197	CbGpPWpGaD
Zafirlukast—CYP1A2—Metabolism—TYMP—urinary bladder cancer	2.21e-05	0.000196	CbGpPWpGaD
Zafirlukast—PTGS1—Metabolism—GSTM1—urinary bladder cancer	2.2e-05	0.000195	CbGpPWpGaD
Zafirlukast—PTGS1—Metabolism—NCOR1—urinary bladder cancer	2.2e-05	0.000195	CbGpPWpGaD
Zafirlukast—CYP2C8—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	2.2e-05	0.000195	CbGpPWpGaD
Zafirlukast—ABCG2—Metabolism—GPX1—urinary bladder cancer	2.19e-05	0.000194	CbGpPWpGaD
Zafirlukast—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	2.19e-05	0.000194	CbGpPWpGaD
Zafirlukast—CYSLTR1—Signaling Pathways—EGFR—urinary bladder cancer	2.19e-05	0.000194	CbGpPWpGaD
Zafirlukast—ABCG2—Metabolism—ERCC2—urinary bladder cancer	2.15e-05	0.000191	CbGpPWpGaD
Zafirlukast—CYP2E1—Metabolism—NQO1—urinary bladder cancer	2.14e-05	0.00019	CbGpPWpGaD
Zafirlukast—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	2.14e-05	0.000189	CbGpPWpGaD
Zafirlukast—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	2.12e-05	0.000188	CbGpPWpGaD
Zafirlukast—PTGS1—Metabolism—GPX1—urinary bladder cancer	2.11e-05	0.000187	CbGpPWpGaD
Zafirlukast—PTGS1—Metabolism—ERCC2—urinary bladder cancer	2.07e-05	0.000183	CbGpPWpGaD
Zafirlukast—CYSLTR1—Signaling Pathways—KRAS—urinary bladder cancer	2.07e-05	0.000183	CbGpPWpGaD
Zafirlukast—CYP2C19—Metabolism—ENO2—urinary bladder cancer	2.05e-05	0.000182	CbGpPWpGaD
Zafirlukast—CYP2C19—Metabolism—HPGDS—urinary bladder cancer	2.05e-05	0.000182	CbGpPWpGaD
Zafirlukast—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	2.04e-05	0.000181	CbGpPWpGaD
Zafirlukast—CYP2D6—Metabolism—RRM2—urinary bladder cancer	2.04e-05	0.000181	CbGpPWpGaD
Zafirlukast—ABCG2—Metabolism—MTHFR—urinary bladder cancer	2.02e-05	0.000179	CbGpPWpGaD
Zafirlukast—CYP2C9—Metabolism—RRM2—urinary bladder cancer	2.02e-05	0.000179	CbGpPWpGaD
Zafirlukast—CYP1A2—Metabolism—NAT2—urinary bladder cancer	2e-05	0.000177	CbGpPWpGaD
Zafirlukast—CYP2C19—Metabolism—GSTT1—urinary bladder cancer	1.99e-05	0.000177	CbGpPWpGaD
Zafirlukast—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.96e-05	0.000174	CbGpPWpGaD
Zafirlukast—PTGS1—Metabolism—MTHFR—urinary bladder cancer	1.94e-05	0.000172	CbGpPWpGaD
Zafirlukast—CYP2D6—Metabolism—ENO2—urinary bladder cancer	1.89e-05	0.000167	CbGpPWpGaD
Zafirlukast—CYP2D6—Metabolism—HPGDS—urinary bladder cancer	1.89e-05	0.000167	CbGpPWpGaD
Zafirlukast—CYP2C9—Metabolism—ENO2—urinary bladder cancer	1.87e-05	0.000166	CbGpPWpGaD
Zafirlukast—CYP2C9—Metabolism—HPGDS—urinary bladder cancer	1.87e-05	0.000166	CbGpPWpGaD
Zafirlukast—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.86e-05	0.000165	CbGpPWpGaD
Zafirlukast—CYP2C8—Metabolism—NQO1—urinary bladder cancer	1.85e-05	0.000164	CbGpPWpGaD
Zafirlukast—CYSLTR1—Signaling Pathways—TP53—urinary bladder cancer	1.84e-05	0.000163	CbGpPWpGaD
Zafirlukast—CYP2D6—Metabolism—GSTT1—urinary bladder cancer	1.83e-05	0.000162	CbGpPWpGaD
Zafirlukast—CYP2C9—Metabolism—GSTT1—urinary bladder cancer	1.81e-05	0.000161	CbGpPWpGaD
Zafirlukast—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.8e-05	0.00016	CbGpPWpGaD
Zafirlukast—CYP2E1—Metabolism—GSTP1—urinary bladder cancer	1.79e-05	0.000159	CbGpPWpGaD
Zafirlukast—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.79e-05	0.000159	CbGpPWpGaD
Zafirlukast—CYSLTR1—Signaling Pathways—HRAS—urinary bladder cancer	1.76e-05	0.000156	CbGpPWpGaD
Zafirlukast—CYP1A2—Metabolism—RRM2—urinary bladder cancer	1.73e-05	0.000153	CbGpPWpGaD
Zafirlukast—CYP3A4—Metabolism—TYMP—urinary bladder cancer	1.71e-05	0.000151	CbGpPWpGaD
Zafirlukast—CYP2E1—Metabolism—TYMS—urinary bladder cancer	1.66e-05	0.000148	CbGpPWpGaD
Zafirlukast—CYP2C19—Metabolism—NQO1—urinary bladder cancer	1.65e-05	0.000147	CbGpPWpGaD
Zafirlukast—CYP2E1—Metabolism—NCOR1—urinary bladder cancer	1.64e-05	0.000146	CbGpPWpGaD
Zafirlukast—CYP2E1—Metabolism—GSTM1—urinary bladder cancer	1.64e-05	0.000146	CbGpPWpGaD
Zafirlukast—ABCG2—Metabolism—PPARG—urinary bladder cancer	1.64e-05	0.000146	CbGpPWpGaD
Zafirlukast—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.61e-05	0.000142	CbGpPWpGaD
Zafirlukast—CYP1A2—Metabolism—HPGDS—urinary bladder cancer	1.6e-05	0.000142	CbGpPWpGaD
Zafirlukast—CYP1A2—Metabolism—ENO2—urinary bladder cancer	1.6e-05	0.000142	CbGpPWpGaD
Zafirlukast—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.59e-05	0.000141	CbGpPWpGaD
Zafirlukast—PTGS1—Metabolism—PPARG—urinary bladder cancer	1.58e-05	0.00014	CbGpPWpGaD
Zafirlukast—ABCG2—Metabolism—CREBBP—urinary bladder cancer	1.58e-05	0.00014	CbGpPWpGaD
Zafirlukast—CYP2E1—Metabolism—GPX1—urinary bladder cancer	1.57e-05	0.00014	CbGpPWpGaD
Zafirlukast—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.57e-05	0.000139	CbGpPWpGaD
Zafirlukast—CYP1A2—Metabolism—GSTT1—urinary bladder cancer	1.55e-05	0.000138	CbGpPWpGaD
Zafirlukast—CYP2C8—Metabolism—GSTP1—urinary bladder cancer	1.55e-05	0.000137	CbGpPWpGaD
Zafirlukast—CYP2E1—Metabolism—ERCC2—urinary bladder cancer	1.55e-05	0.000137	CbGpPWpGaD
Zafirlukast—CYP3A4—Metabolism—NAT2—urinary bladder cancer	1.54e-05	0.000137	CbGpPWpGaD
Zafirlukast—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.53e-05	0.000136	CbGpPWpGaD
Zafirlukast—CYP2D6—Metabolism—NQO1—urinary bladder cancer	1.52e-05	0.000135	CbGpPWpGaD
Zafirlukast—PTGS1—Metabolism—CREBBP—urinary bladder cancer	1.51e-05	0.000134	CbGpPWpGaD
Zafirlukast—CYP2C9—Metabolism—NQO1—urinary bladder cancer	1.51e-05	0.000134	CbGpPWpGaD
Zafirlukast—CYP2C8—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.5e-05	0.000133	CbGpPWpGaD
Zafirlukast—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.46e-05	0.00013	CbGpPWpGaD
Zafirlukast—CYP2E1—Metabolism—MTHFR—urinary bladder cancer	1.45e-05	0.000129	CbGpPWpGaD
Zafirlukast—CYP2C8—Metabolism—TYMS—urinary bladder cancer	1.44e-05	0.000128	CbGpPWpGaD
Zafirlukast—CYP2C8—Metabolism—GSTM1—urinary bladder cancer	1.42e-05	0.000126	CbGpPWpGaD
Zafirlukast—CYP2C8—Metabolism—NCOR1—urinary bladder cancer	1.42e-05	0.000126	CbGpPWpGaD
Zafirlukast—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.4e-05	0.000124	CbGpPWpGaD
Zafirlukast—CYP2C19—Metabolism—GSTP1—urinary bladder cancer	1.38e-05	0.000122	CbGpPWpGaD
Zafirlukast—CYP2C8—Metabolism—GPX1—urinary bladder cancer	1.36e-05	0.000121	CbGpPWpGaD
Zafirlukast—CYP2C8—Metabolism—ERCC2—urinary bladder cancer	1.34e-05	0.000118	CbGpPWpGaD
Zafirlukast—CYP2C19—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.33e-05	0.000118	CbGpPWpGaD
Zafirlukast—CYP3A4—Metabolism—RRM2—urinary bladder cancer	1.33e-05	0.000118	CbGpPWpGaD
Zafirlukast—ABCG2—Metabolism—PTGS2—urinary bladder cancer	1.29e-05	0.000114	CbGpPWpGaD
Zafirlukast—CYP1A2—Metabolism—NQO1—urinary bladder cancer	1.29e-05	0.000114	CbGpPWpGaD
Zafirlukast—CYP2C19—Metabolism—TYMS—urinary bladder cancer	1.28e-05	0.000114	CbGpPWpGaD
Zafirlukast—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.28e-05	0.000113	CbGpPWpGaD
Zafirlukast—CYP2D6—Metabolism—GSTP1—urinary bladder cancer	1.27e-05	0.000113	CbGpPWpGaD
Zafirlukast—CYP2C19—Metabolism—NCOR1—urinary bladder cancer	1.27e-05	0.000112	CbGpPWpGaD
Zafirlukast—CYP2C19—Metabolism—GSTM1—urinary bladder cancer	1.27e-05	0.000112	CbGpPWpGaD
Zafirlukast—CYP2C9—Metabolism—GSTP1—urinary bladder cancer	1.26e-05	0.000112	CbGpPWpGaD
Zafirlukast—CYP2C8—Metabolism—MTHFR—urinary bladder cancer	1.26e-05	0.000111	CbGpPWpGaD
Zafirlukast—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.25e-05	0.000111	CbGpPWpGaD
Zafirlukast—PTGS1—Metabolism—PTGS2—urinary bladder cancer	1.24e-05	0.00011	CbGpPWpGaD
Zafirlukast—CYP3A4—Metabolism—ENO2—urinary bladder cancer	1.23e-05	0.000109	CbGpPWpGaD
Zafirlukast—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	1.23e-05	0.000109	CbGpPWpGaD
Zafirlukast—CYP2C9—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.22e-05	0.000108	CbGpPWpGaD
Zafirlukast—CYP2C19—Metabolism—GPX1—urinary bladder cancer	1.21e-05	0.000108	CbGpPWpGaD
Zafirlukast—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	1.2e-05	0.000106	CbGpPWpGaD
Zafirlukast—CYP2C19—Metabolism—ERCC2—urinary bladder cancer	1.19e-05	0.000106	CbGpPWpGaD
Zafirlukast—CYP2D6—Metabolism—TYMS—urinary bladder cancer	1.18e-05	0.000105	CbGpPWpGaD
Zafirlukast—CYP2E1—Metabolism—PPARG—urinary bladder cancer	1.18e-05	0.000104	CbGpPWpGaD
Zafirlukast—CYP2C9—Metabolism—TYMS—urinary bladder cancer	1.17e-05	0.000104	CbGpPWpGaD
Zafirlukast—CYP2D6—Metabolism—NCOR1—urinary bladder cancer	1.17e-05	0.000103	CbGpPWpGaD
Zafirlukast—CYP2D6—Metabolism—GSTM1—urinary bladder cancer	1.17e-05	0.000103	CbGpPWpGaD
Zafirlukast—CYP2C9—Metabolism—NCOR1—urinary bladder cancer	1.16e-05	0.000103	CbGpPWpGaD
Zafirlukast—CYP2C9—Metabolism—GSTM1—urinary bladder cancer	1.16e-05	0.000103	CbGpPWpGaD
Zafirlukast—CYP2E1—Metabolism—CREBBP—urinary bladder cancer	1.13e-05	0.0001	CbGpPWpGaD
Zafirlukast—ABCG2—Metabolism—PTEN—urinary bladder cancer	1.13e-05	9.98e-05	CbGpPWpGaD
Zafirlukast—CYP2C19—Metabolism—MTHFR—urinary bladder cancer	1.12e-05	9.94e-05	CbGpPWpGaD
Zafirlukast—CYP2D6—Metabolism—GPX1—urinary bladder cancer	1.12e-05	9.91e-05	CbGpPWpGaD
Zafirlukast—CYP2C9—Metabolism—GPX1—urinary bladder cancer	1.11e-05	9.82e-05	CbGpPWpGaD
Zafirlukast—CYP2D6—Metabolism—ERCC2—urinary bladder cancer	1.1e-05	9.73e-05	CbGpPWpGaD
Zafirlukast—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.09e-05	9.68e-05	CbGpPWpGaD
Zafirlukast—CYP2C9—Metabolism—ERCC2—urinary bladder cancer	1.09e-05	9.64e-05	CbGpPWpGaD
Zafirlukast—PTGS1—Metabolism—PTEN—urinary bladder cancer	1.08e-05	9.59e-05	CbGpPWpGaD
Zafirlukast—CYP1A2—Metabolism—GSTP1—urinary bladder cancer	1.08e-05	9.54e-05	CbGpPWpGaD
Zafirlukast—ABCG2—Metabolism—EP300—urinary bladder cancer	1.07e-05	9.52e-05	CbGpPWpGaD
Zafirlukast—CYP1A2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.04e-05	9.23e-05	CbGpPWpGaD
Zafirlukast—PTGS1—Metabolism—EP300—urinary bladder cancer	1.03e-05	9.15e-05	CbGpPWpGaD
Zafirlukast—CYP2D6—Metabolism—MTHFR—urinary bladder cancer	1.03e-05	9.14e-05	CbGpPWpGaD
Zafirlukast—CYP2C9—Metabolism—MTHFR—urinary bladder cancer	1.02e-05	9.07e-05	CbGpPWpGaD
Zafirlukast—CYP2C8—Metabolism—PPARG—urinary bladder cancer	1.02e-05	9.03e-05	CbGpPWpGaD
Zafirlukast—CYP1A2—Metabolism—TYMS—urinary bladder cancer	9.99e-06	8.87e-05	CbGpPWpGaD
Zafirlukast—CYP3A4—Metabolism—NQO1—urinary bladder cancer	9.95e-06	8.83e-05	CbGpPWpGaD
Zafirlukast—CYP1A2—Metabolism—NCOR1—urinary bladder cancer	9.88e-06	8.77e-05	CbGpPWpGaD
Zafirlukast—CYP1A2—Metabolism—GSTM1—urinary bladder cancer	9.88e-06	8.77e-05	CbGpPWpGaD
Zafirlukast—CYP2C8—Metabolism—CREBBP—urinary bladder cancer	9.78e-06	8.68e-05	CbGpPWpGaD
Zafirlukast—CYP1A2—Metabolism—GPX1—urinary bladder cancer	9.46e-06	8.39e-05	CbGpPWpGaD
Zafirlukast—CYP1A2—Metabolism—ERCC2—urinary bladder cancer	9.29e-06	8.24e-05	CbGpPWpGaD
Zafirlukast—CYP2E1—Metabolism—PTGS2—urinary bladder cancer	9.26e-06	8.22e-05	CbGpPWpGaD
Zafirlukast—CYP2C19—Metabolism—PPARG—urinary bladder cancer	9.09e-06	8.06e-05	CbGpPWpGaD
Zafirlukast—CYP1A2—Metabolism—MTHFR—urinary bladder cancer	8.73e-06	7.75e-05	CbGpPWpGaD
Zafirlukast—CYP2C19—Metabolism—CREBBP—urinary bladder cancer	8.73e-06	7.74e-05	CbGpPWpGaD
Zafirlukast—CYP2D6—Metabolism—PPARG—urinary bladder cancer	8.36e-06	7.42e-05	CbGpPWpGaD
Zafirlukast—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	8.3e-06	7.36e-05	CbGpPWpGaD
Zafirlukast—CYP2C9—Metabolism—PPARG—urinary bladder cancer	8.29e-06	7.35e-05	CbGpPWpGaD
Zafirlukast—CYP2E1—Metabolism—PTEN—urinary bladder cancer	8.08e-06	7.17e-05	CbGpPWpGaD
Zafirlukast—CYP2D6—Metabolism—CREBBP—urinary bladder cancer	8.03e-06	7.12e-05	CbGpPWpGaD
Zafirlukast—CYP2C8—Metabolism—PTGS2—urinary bladder cancer	8.01e-06	7.11e-05	CbGpPWpGaD
Zafirlukast—CYP2C9—Metabolism—CREBBP—urinary bladder cancer	7.96e-06	7.06e-05	CbGpPWpGaD
Zafirlukast—CYP3A4—Metabolism—TYMS—urinary bladder cancer	7.71e-06	6.84e-05	CbGpPWpGaD
Zafirlukast—CYP2E1—Metabolism—EP300—urinary bladder cancer	7.71e-06	6.84e-05	CbGpPWpGaD
Zafirlukast—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	7.62e-06	6.76e-05	CbGpPWpGaD
Zafirlukast—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	7.62e-06	6.76e-05	CbGpPWpGaD
Zafirlukast—CYP3A4—Metabolism—GPX1—urinary bladder cancer	7.3e-06	6.48e-05	CbGpPWpGaD
Zafirlukast—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	7.17e-06	6.36e-05	CbGpPWpGaD
Zafirlukast—CYP2C19—Metabolism—PTGS2—urinary bladder cancer	7.15e-06	6.34e-05	CbGpPWpGaD
Zafirlukast—CYP1A2—Metabolism—PPARG—urinary bladder cancer	7.08e-06	6.28e-05	CbGpPWpGaD
Zafirlukast—CYP2C8—Metabolism—PTEN—urinary bladder cancer	6.98e-06	6.2e-05	CbGpPWpGaD
Zafirlukast—CYP1A2—Metabolism—CREBBP—urinary bladder cancer	6.8e-06	6.03e-05	CbGpPWpGaD
Zafirlukast—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	6.74e-06	5.98e-05	CbGpPWpGaD
Zafirlukast—CYP2C8—Metabolism—EP300—urinary bladder cancer	6.66e-06	5.91e-05	CbGpPWpGaD
Zafirlukast—CYP2D6—Metabolism—PTGS2—urinary bladder cancer	6.57e-06	5.83e-05	CbGpPWpGaD
Zafirlukast—CYP2C9—Metabolism—PTGS2—urinary bladder cancer	6.52e-06	5.78e-05	CbGpPWpGaD
Zafirlukast—CYP2C19—Metabolism—PTEN—urinary bladder cancer	6.23e-06	5.53e-05	CbGpPWpGaD
Zafirlukast—CYP2C19—Metabolism—EP300—urinary bladder cancer	5.94e-06	5.27e-05	CbGpPWpGaD
Zafirlukast—CYP2D6—Metabolism—PTEN—urinary bladder cancer	5.73e-06	5.09e-05	CbGpPWpGaD
Zafirlukast—CYP2C9—Metabolism—PTEN—urinary bladder cancer	5.68e-06	5.04e-05	CbGpPWpGaD
Zafirlukast—CYP1A2—Metabolism—PTGS2—urinary bladder cancer	5.57e-06	4.94e-05	CbGpPWpGaD
Zafirlukast—CYP2D6—Metabolism—EP300—urinary bladder cancer	5.47e-06	4.85e-05	CbGpPWpGaD
Zafirlukast—CYP3A4—Metabolism—PPARG—urinary bladder cancer	5.46e-06	4.85e-05	CbGpPWpGaD
Zafirlukast—CYP2C9—Metabolism—EP300—urinary bladder cancer	5.42e-06	4.81e-05	CbGpPWpGaD
Zafirlukast—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	5.25e-06	4.66e-05	CbGpPWpGaD
Zafirlukast—CYP1A2—Metabolism—PTEN—urinary bladder cancer	4.86e-06	4.31e-05	CbGpPWpGaD
Zafirlukast—CYP1A2—Metabolism—EP300—urinary bladder cancer	4.63e-06	4.11e-05	CbGpPWpGaD
Zafirlukast—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	4.3e-06	3.81e-05	CbGpPWpGaD
Zafirlukast—CYP3A4—Metabolism—PTEN—urinary bladder cancer	3.75e-06	3.33e-05	CbGpPWpGaD
Zafirlukast—CYP3A4—Metabolism—EP300—urinary bladder cancer	3.57e-06	3.17e-05	CbGpPWpGaD
